High-throughput docking as a source of novel drug leads

Current Opinion in Chemical Biology

Volumn 8, Issue 4, 2004, Pages 365-370

  Alvarez, Juan C ^a  

^a PFIZER INC   (United States)

Author keywords

high throughput docking; high throughput screening; HTD; HTS; IMPDH; inosine 5 monophosphate dehydrogenase; MASC; Multiple Active Site Correction; PfDHFR; Plasmodium falciparum dihydrofolate reductase; SAR; structure activity relationship; VS

Indexed keywords

BETA LACTAMASE INHIBITOR; CYCLOPHILIN; ENZYME INHIBITOR; INDOLE DERIVATIVE; PHOSPHOTRANSFERASE INHIBITOR; PROTEIN KINASE INHIBITOR; PYRIMIDINE; QUINAZOLINE DERIVATIVE;

ACCURACY; BIOAVAILABILITY; COST; DRUG INDUSTRY; DRUG SCREENING; HUMAN; MEDICAL INFORMATION; MEDICAL TECHNOLOGY; MOLECULAR DYNAMICS; MOLECULAR RECOGNITION; NONHUMAN; PROTEIN FUNCTION; REVIEW; SCORING SYSTEM;

BINDING SITES; COMPUTER-AIDED DESIGN; DRUG DESIGN; LIGANDS; PROTEINS; STRUCTURE-ACTIVITY RELATIONSHIP;

PLASMODIUM FALCIPARUM;

EID: 3242884966     PISSN: 13675931     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cbpa.2004.05.001     Document Type: Review

References (51)

1. Bajorath J. Integration of virtual and high-throughput screening. Nat Rev Drug Discov. 1:2002;882-894
2. Lengauer T., Lemmen C., Rarey M., Zimmermann M. Novel technologies for virtual screening. Drug Discov Today. 9:2004;27-34
3. Xu H., Agrafiotis D.K. Retrospect and prospect of virtual screening in drug discovery. Curr Top Med Chem. 2:2002;1305-1320
4. Oprea TI, Matter H: Integrating virtual screening in lead discovery. Curr Opin Chem Biol 2004, 8:in press.
5. Fischer E. Einfluss der Configuration auf die wirkung der Enzyme. Ber Dt Chem Ges. 27:1894;2985-2993
6. Brooijmans N., Kuntz I.D. Molecular recognition and docking algorithms. Annu Rev Biophys Biomol Struct. 32:2003;335-373 An outstanding review on most of the technical aspects of molecular docking.
7. Glen R.C., Allen S.C. Ligand-protein docking: cancer research at the interface between biology and chemistry. Curr Med Chem. 10:2003;763-777
8. Halperin I., Ma B., Wolfson H., Nussinov R. Principles of docking: an overview of search algorithms and a guide to scoring functions. Proteins. 47:2002;409-443
9. Wang R., Lu Y., Wang S. Comparative evaluation of 11 scoring functions for molecular docking. J Med Chem. 46:2003;2287-2303
10. Hann M, Oprea TI: Pursuing the leadlikeness concept in pharmaceutical research. Curr Opin Chem Biol 2004, 8:in press.
11. Oprea T.I., Davis A.M., Teague S.J., Leeson P.D. Is there a difference between leads and drugs? A historical perspective. J Chem Inf Comput Sci. 41:2001;1308-1315
12. Lipinski C.A., Lombardo F., Dominy B.W., Feeney P.J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev. 46:1997;3-26
13. Vangrevelinghe E., Zimmermann K., Schoepfer J., Portmann R., Fabbro D., Furet P. Discovery of a potent and selective protein kinase CK2 inhibitor by high-throughput docking. J Med Chem. 46:2003;2656-2662
14. Ewing T.J., Makino S., Skillman A.G., Kuntz I.D. DOCK 4.0: search strategies for automated molecular docking of flexible molecule databases. J Comput Aided Mol Des. 15:2001;411-428
15. Wu S.Y., McNae I., Kontopidis G., McClue S.J., McInnes C., Stewart K.J., Wang S., Zheleva D.I., Marriage H., Lane D.P., et al. Discovery of a novel family of CDK inhibitors with the program LIDAEUS: structural basis for ligand-induced disordering of the activation loop. Structure. 11:2003;399-410
16. Powers R.A., Morandi F., Shoichet B.K. Structure-based discovery of a novel, noncovalent inhibitor of AmpC beta-lactamase. Structure (Camb). 10:2002;1013-1023
17. Soelaiman S., Wei B.Q., Bergson P., Lee Y.S., Shen Y., Mrksich M., Shoichet B.K., Tang W.J. Structure-based inhibitor discovery against adenylyl cyclase toxins from pathogenic bacteria that cause anthrax and whooping cough. J Biol Chem. 278:2003;25990-25997 The authors went through significant effort to validate the hits from the virtual screen, eliminating the possibility that the inhibition observed is due to a spurious mechanism.
18. Lorber D.M., Shoichet B.K. Flexible ligand docking using conformational ensembles. Protein Sci. 7:1998;938-950
19. McGovern S.L., Shoichet B.K. Kinase inhibitors: not just for kinases anymore. J Med Chem. 46:2003;1478-1483
20. McGovern S.L., Caselli E., Grigorieff N., Shoichet B.K. A common mechanism underlying promiscuous inhibitors from virtual and high-throughput screening. J Med Chem. 45:2002;1712-1722
21. Seidler J., McGovern S.L., Doman T.N., Shoichet B.K. Identification and prediction of promiscuous aggregating inhibitors among known drugs. J Med Chem. 46:2003;4477-4486
22. McGovern S.L., Helfand B.T., Feng B., Shoichet B.K. A specific mechanism of nonspecific inhibition. J Med Chem. 46:2003;4265-4272 A continuation of the characterization of non-specific inhibition (also see [18]). The addition of detergent reverses the action of inhibitory aggregates, providing a simple and practical solution to reducing the number of false positives found by HTS and VS.
23. Pickett S.D., Sherborne B.S., Wilkinson T., Bennett J., Borkakoti N., Broadhurst M., Hurst D., Kilford I., McKinnell M., Jones P.S. Discovery of novel low molecular weight inhibitors of IMPDH via virtual needle screening. Bioorg Med Chem Lett. 13:2003;1691-1694
24. Rarey M., Kramer B., Lengauer T., Klebe G. A fast flexible docking method using an incremental construction algorithm. J Mol Biol. 261:1996;470-489
25. Stahl M., Rarey M. Detailed analysis of scoring functions for virtual screening. J Med Chem. 44:2001;1035-1042
26. Brenk R., Naerum L., Gradler U., Gerber H-D., Garcia G.A., Reuter K., Stubbs M.T., Klebe G. Virtual screening for submicromolar leads of tRNA-guanine transglycosylase based on a new unexpected binding mode detected by crystal structure analysis. J Med Chem. 46:2003;1133-1143
27. Westerfors M., Tedebark U., Andersson H.O., Ohrman S., Choudhury D., Ersoy O., Shinohara Y., Axen A., Carredano E., Baumann H. Structure-based discovery of a new affinity ligand to pancreatic alpha-amylase. J Mol Recognit. 16:2003;396-405
28. Wu Y-Q., Belyakov S., Chi Choi, Limburg D., Thomas B.E. IV, Vaal M., Wei L., Wilkinson D.E., Holmes A., Fuller M., et al. Synthesis and biological evaluation of non-peptidic cyclophilin ligands. J Med Chem. 46:2003;1112-1115
29. Rastelli G., Pacchioni S., Sirawaraporn W., Sirawaraporn R., Parenti M.D., Ferrari A.M. Docking and database screening reveal new classes of Plasmodium falciparum dihydrofolate reductase inhibitors. J Med Chem. 46:2003;2834-2845
30. Singh J., Chuaqui C.E., Boriack-Sjodin P.A., Wen-Cherng Lee, Pontz T., Corbley M.J., Cheung H.-K., Arduini R.M., Mead J.N., Newman M.N., et al. Successful shape-based virtual screening: the discovery of a potent inhibitor of the Type I TGF_ receptor kinase (T_RI). Bioorg Med Chem Lett. 13:2003;4355-4359
31. Carlson H.A. Protein flexibility and drug design: how to hit a moving target. Curr Opin Chem Biol. 6:2002;447-452
32. Verdonk M.L., Cole J.C., Hartshorn M.J., Murray C.W., Taylor R.D. Improved protein-ligand docking using GOLD. Proteins. 52:2003;609-623
33. Charifson P.S., Corkery J.J., Murcko M.A., Walters W.P. Consensus scoring: a method for obtaining improved hit rates from docking databases of three-dimensional structures into proteins. J Med Chem. 42:1999;5100-5109
34. Kuntz I.D., Chen K., Sharp K.A., Kollman P.A. The maximal affinity of ligands. Proc Natl Acad Sci USA. 96:1999;9997-10002
35. Pan Y., Huang N., Cho S., MacKerell A.D. Jr. Consideration of molecular weight during compound selection in virtual target-based database screening. J Chem Inf Comput Sci. 43:2003;267-272
36. Vigers G.P.A., Rizzi J.P. Multiple active site corrections for docking and virtual screening. J Med Chem. 47:2004;80-89
37. Joseph-McCarthy D., Thomas B.E. IV, Belmarsh M., Moustakas D., Alvarez J.C. Pharmacophore-based molecular docking to account for ligand flexibility. Proteins. 51:2003;172-188 The authors describe a new method for HTD consisting of constrained rigid docking of conformer ensembles using theoretical pharmacophoric sites on the target protein, The method is extremely fast due to the efficient coverage of ligand conformer and orientational space.
38. Miranker A., Karplus M. Functionality maps of binding sites: a multiple copy simultaneous search method. Proteins. 11:1991;29-34
39. Joseph-McCarthy D., Alvarez J.C. Automated generation of MCSS-derived pharmacophoric DOCK site points for searching multiconformation databases. Proteins. 51:2003;189-202
40. Shoichet B.K., Kuntz I.D. Matching chemistry and shape in molecular docking. Protein Eng. 6:1993;723-732
41. Good A.C., Cheney D.L., Sitkoff D.F., Tokarski J.S., Stouch T.R., Bassolino D.A., Krystek S.R., Yi L., Masonb J.S., Perkins T.D.J. Analysis and optimization of structure-based virtual screening protocols 2. Examination of docked ligand orientation sampling methodology: mapping a pharmacophore for success. J Mol Graph Model. 22:2003;31-40
42. Erickson J.A., Jalaie M., Robertson D.H., Lewis R.A., Vieth M. Lessons in molecular recognition: the effects of ligand and protein flexibility on molecular docking accuracy. J Med Chem. 47:2004;45-55
43. Kallblad P., Dean P.M. Efficient conformational sampling of local side-chain flexibility. J Mol Biol. 326:2003;1651-1665
44. McGovern S.L., Shoichet B.K. Information decay in molecular docking screens against holo, apo, and modeled conformations of enzymes. J Med Chem. 46:2003;2895-2907
45. Birch L., Murray C.W., Hartshorn M.J., Tickle I.J., Verdonk M.L. Sensitivity of molecular docking to induced fit effects in influenza virus neuraminidase. J Comput Aided Mol Des. 16:2002;855-869 An excellent study highlighting the sensitivity of docking methodologies to protein structure through cross-docking experiments.
46. Davis A.M., Teague S.J., Kleywegt G.J. Application and limitations of X-ray crystallographic data in structure-based ligand and drug design. Angew Chem Int Ed Engl. 42:2003;2718-2736
47. Wang J., Morin P., Wang W., Kollman P.A. Use of MM-PBSA in reproducing the binding free energies to HIV-1 RT of TIBO derivatives and predicting the binding mode to HIV-1 RT of efavirenz by docking and MM-PBSA. J Am Chem Soc. 123:2001;5221-5230
48. Huo S., Wang J., Cieplak P., Kollman P.A., Kuntz I.D. Molecular dynamics and free energy analyses of cathepsin D-inhibitor interactions: insight into structure-based ligand design. J Med Chem. 45:2002;1412-1419 The authors use a molecular dynamics-based, continuum solvent method (MM-PBSA) to reproduce the experimental binding affinity for a set of seven inhibitors to cathepsin-D. The integration of these types of calculations into the HTD paradigm will significantly increase the accuracy of the methods.
49. Peng H., Huang N., Qi J., Xie P., Xu C., Wang J., Yang C. Identification of novel inhibitors of BCR-ABL tyrosine kinase via virtual screening. Bioorg Med Chem Lett. 13:2003;3693-3699
50. Liu H., Li Y., Song M., Tan X., Cheng F., Zheng S., Shen J., Luo X., Ji R., Yue J., et al. Structure-based discovery of potassium channel blockers from natural products: virtual screening and electrophysiological assay testing. Chem Biol. 10:2003;1103-1113
51. Schapira M., Raaka B.M., Das S., Fan L., Totrov M., Zhou Z., Wilson S.R., Abagyan R., Samuels H.H. Discovery of diverse thyroid hormone receptor antagonists by high-throughput docking. Proc Natl Acad Sci USA. 100:2003;7354-7359